References
- 1. Scheiber I.F., Brůha R., Dušek P. (2017) Pathogenesis of Wilson disease. Handb. Clin. Neurol., 142: 43–55. doi: 10.1016/B978-0-444-63625-6.00005-7.
- 2. Stapelbroek J.M., Bollen C.W., van Amstel J.K. et al. (2004) The H1069Q mutation in ATP7B is associated with late and neurologic presentation in Wilson disease: results of a meta-analysis. J. Hepatol., 41(5): 758–763. doi: 10.1016/j.jhep.2004.07.017.
- 3. Pfeiffer R.F. (2016) Wilson Disease. Continuum (Minneap. Minn.), 22(4 Movement Disorders): 1246–1261. doi: 10.1212/CON.0000000000000350.
- 4. http://www.dec.gov.ua/wp-content/uploads/2019/11/2016_769_ykpmd_vils.pdf.
- 5. Członkowska A., Litwin T., Chabik G. (2017) Wilson disease: neurologic features. Handb. Clin. Neurol., 142: 101–119. doi: 10.1016/B978-0-444-63625-6.00010-0.
- 6. EASL (2012) Clinical Practice Guidelines: Wilson’s disease. J. Hepatol., 56: 671–685.
- 7. Taly A.B., Meenakshi-Sundaram S., Sinha S. et al. (2007) Wilson disease: description of 282 patients evaluated over 3 decades. Medicine (Baltimore), 86(2): 112–121. doi: 10.1097/MD.0b013e318045a00e.
- 8. Mahjoub F., Fereiduni R., Jahanzad I. et al. (2012) Atomic Absorption Spectrometry in Wilson’s Disease and Its Comparison with Other Laboratory Tests and Paraclinical Findings. Iran J. Pediatr., 22(1): 52–56. PMID: 23056859.
- 9. Hermann W. (2019) Classification and differential diagnosis of Wilson’s disease. Ann. Transl. Med., 7(Suppl. 2): S63. doi: 10.21037/atm.2019.02.07.
- 10. Schilsky M.L. (2017) Wilson Disease: Diagnosis, Treatment, and Follow-up. Clin. Liver Dis., 21(4): 755–767. doi: 10.1016/j.cld.2017.06.011.
- 11. search.ligazakon.ua/l_doc2.nsf/link1/MOZ26291.html.
- 12. Brewer G.J., Terry C.A., Aisen A.M., Hill G.M. (1987) Worsening of neurologic syndrome in patients with Wilson’s disease with initial penicillamine therapy. Arch. Neurol., 44(5): 490–493. doi: 10.1001/archneur.1987.00520170020016.